The logistics and coordination of respiratory syncytial virus immunoprophylaxis use among US pediatric specialists

Pierre C. Wong, Prabhu Parimi, Joseph B. Domachowske, Deborah M. Friedman, Michael G. Marcus, Daniel F. Garcia, William V. La Via, Iqra A. Syed, Shelagh M. Szabo, Kimmie K. McLaurin, Veena R. Kumar

Research output: Contribution to journalArticle

Abstract

This study was conducted to survey US pediatric specialists about administration of respiratory syncytial virus (RSV) immunoprophylaxis, communication patterns among physicians and parents, and barriers to access. Separate surveys were sent to neonatologists, pediatricians, pediatric pulmonologists, and pediatric cardiologists. Most physicians (≥93.5%) routinely recommended immunoprophylaxis to high-risk children. Most respondents (≥71.8%) reported that >50.0% of eligible infants and young children received each monthly dose throughout the RSV season, with the first dose most commonly administered before discharge from the birth hospitalization. To ensure receipt of subsequent doses, specialists frequently scheduled a follow-up visit at the end of the current appointment. All specialists reported insurance denials as the biggest obstacle to the administration of immunoprophylaxis to high-risk children. These findings may be used to improve adherence to immunoprophylaxis by enhancing education and physician-parent communications about severe RSV disease prevention, and by reducing known barriers to use of this preventive therapy.

Original languageEnglish (US)
Pages (from-to)1230-1241
Number of pages12
JournalClinical Pediatrics
Volume55
Issue number13
DOIs
StatePublished - Nov 1 2016
Externally publishedYes

Fingerprint

Respiratory Syncytial Viruses
Pediatrics
Physicians
Communication
Virus Diseases
Insurance
Appointments and Schedules
Hospitalization
Parents
Parturition
Education
Surveys and Questionnaires
Therapeutics

Keywords

  • cardiologist
  • neonatologist
  • palivizumab
  • pediatrician
  • pulmonologist
  • RSV

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Wong, P. C., Parimi, P., Domachowske, J. B., Friedman, D. M., Marcus, M. G., Garcia, D. F., ... Kumar, V. R. (2016). The logistics and coordination of respiratory syncytial virus immunoprophylaxis use among US pediatric specialists. Clinical Pediatrics, 55(13), 1230-1241. https://doi.org/10.1177/0009922815621343

The logistics and coordination of respiratory syncytial virus immunoprophylaxis use among US pediatric specialists. / Wong, Pierre C.; Parimi, Prabhu; Domachowske, Joseph B.; Friedman, Deborah M.; Marcus, Michael G.; Garcia, Daniel F.; La Via, William V.; Syed, Iqra A.; Szabo, Shelagh M.; McLaurin, Kimmie K.; Kumar, Veena R.

In: Clinical Pediatrics, Vol. 55, No. 13, 01.11.2016, p. 1230-1241.

Research output: Contribution to journalArticle

Wong, PC, Parimi, P, Domachowske, JB, Friedman, DM, Marcus, MG, Garcia, DF, La Via, WV, Syed, IA, Szabo, SM, McLaurin, KK & Kumar, VR 2016, 'The logistics and coordination of respiratory syncytial virus immunoprophylaxis use among US pediatric specialists', Clinical Pediatrics, vol. 55, no. 13, pp. 1230-1241. https://doi.org/10.1177/0009922815621343
Wong, Pierre C. ; Parimi, Prabhu ; Domachowske, Joseph B. ; Friedman, Deborah M. ; Marcus, Michael G. ; Garcia, Daniel F. ; La Via, William V. ; Syed, Iqra A. ; Szabo, Shelagh M. ; McLaurin, Kimmie K. ; Kumar, Veena R. / The logistics and coordination of respiratory syncytial virus immunoprophylaxis use among US pediatric specialists. In: Clinical Pediatrics. 2016 ; Vol. 55, No. 13. pp. 1230-1241.
@article{9d6751944640461fa255ceee2dabe66d,
title = "The logistics and coordination of respiratory syncytial virus immunoprophylaxis use among US pediatric specialists",
abstract = "This study was conducted to survey US pediatric specialists about administration of respiratory syncytial virus (RSV) immunoprophylaxis, communication patterns among physicians and parents, and barriers to access. Separate surveys were sent to neonatologists, pediatricians, pediatric pulmonologists, and pediatric cardiologists. Most physicians (≥93.5{\%}) routinely recommended immunoprophylaxis to high-risk children. Most respondents (≥71.8{\%}) reported that >50.0{\%} of eligible infants and young children received each monthly dose throughout the RSV season, with the first dose most commonly administered before discharge from the birth hospitalization. To ensure receipt of subsequent doses, specialists frequently scheduled a follow-up visit at the end of the current appointment. All specialists reported insurance denials as the biggest obstacle to the administration of immunoprophylaxis to high-risk children. These findings may be used to improve adherence to immunoprophylaxis by enhancing education and physician-parent communications about severe RSV disease prevention, and by reducing known barriers to use of this preventive therapy.",
keywords = "cardiologist, neonatologist, palivizumab, pediatrician, pulmonologist, RSV",
author = "Wong, {Pierre C.} and Prabhu Parimi and Domachowske, {Joseph B.} and Friedman, {Deborah M.} and Marcus, {Michael G.} and Garcia, {Daniel F.} and {La Via}, {William V.} and Syed, {Iqra A.} and Szabo, {Shelagh M.} and McLaurin, {Kimmie K.} and Kumar, {Veena R.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1177/0009922815621343",
language = "English (US)",
volume = "55",
pages = "1230--1241",
journal = "Clinical Pediatrics",
issn = "0009-9228",
publisher = "SAGE Publications Inc.",
number = "13",

}

TY - JOUR

T1 - The logistics and coordination of respiratory syncytial virus immunoprophylaxis use among US pediatric specialists

AU - Wong, Pierre C.

AU - Parimi, Prabhu

AU - Domachowske, Joseph B.

AU - Friedman, Deborah M.

AU - Marcus, Michael G.

AU - Garcia, Daniel F.

AU - La Via, William V.

AU - Syed, Iqra A.

AU - Szabo, Shelagh M.

AU - McLaurin, Kimmie K.

AU - Kumar, Veena R.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - This study was conducted to survey US pediatric specialists about administration of respiratory syncytial virus (RSV) immunoprophylaxis, communication patterns among physicians and parents, and barriers to access. Separate surveys were sent to neonatologists, pediatricians, pediatric pulmonologists, and pediatric cardiologists. Most physicians (≥93.5%) routinely recommended immunoprophylaxis to high-risk children. Most respondents (≥71.8%) reported that >50.0% of eligible infants and young children received each monthly dose throughout the RSV season, with the first dose most commonly administered before discharge from the birth hospitalization. To ensure receipt of subsequent doses, specialists frequently scheduled a follow-up visit at the end of the current appointment. All specialists reported insurance denials as the biggest obstacle to the administration of immunoprophylaxis to high-risk children. These findings may be used to improve adherence to immunoprophylaxis by enhancing education and physician-parent communications about severe RSV disease prevention, and by reducing known barriers to use of this preventive therapy.

AB - This study was conducted to survey US pediatric specialists about administration of respiratory syncytial virus (RSV) immunoprophylaxis, communication patterns among physicians and parents, and barriers to access. Separate surveys were sent to neonatologists, pediatricians, pediatric pulmonologists, and pediatric cardiologists. Most physicians (≥93.5%) routinely recommended immunoprophylaxis to high-risk children. Most respondents (≥71.8%) reported that >50.0% of eligible infants and young children received each monthly dose throughout the RSV season, with the first dose most commonly administered before discharge from the birth hospitalization. To ensure receipt of subsequent doses, specialists frequently scheduled a follow-up visit at the end of the current appointment. All specialists reported insurance denials as the biggest obstacle to the administration of immunoprophylaxis to high-risk children. These findings may be used to improve adherence to immunoprophylaxis by enhancing education and physician-parent communications about severe RSV disease prevention, and by reducing known barriers to use of this preventive therapy.

KW - cardiologist

KW - neonatologist

KW - palivizumab

KW - pediatrician

KW - pulmonologist

KW - RSV

UR - http://www.scopus.com/inward/record.url?scp=84991449500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991449500&partnerID=8YFLogxK

U2 - 10.1177/0009922815621343

DO - 10.1177/0009922815621343

M3 - Article

VL - 55

SP - 1230

EP - 1241

JO - Clinical Pediatrics

JF - Clinical Pediatrics

SN - 0009-9228

IS - 13

ER -